Back to Authors

Bogunovic, Dusan

0000-0002-0683-6920

Mayo Clinic

Columbia Center for Genetic Errors of Immunity, Department of Pediatrics, Columbia University Irving Medical Center, New York, NY 10032, USA.

Citations 1

Loss of the kinases TBK1 and IKKε sensitizes target cancer cells to T cell killing through an IFN-γ–mediated inflammatory death program
Sun, N , Carr, Allison R. , Krogman, Erica N., Chawla, Yogesh , Zhong, Jun , Guttormson, Matthew C. , Chan, Mark , Hsu, Michelle A. , Dong, Haidong , Patel, Roosheel S. , Pandey, Akhilesh , Rogers, Laura M. , Ting, Adrian T. , Sun, Nicholas D , Bogunovic, Dusan , Pandey, Akhilesh , Dong, Haidong , Ting, Adrian T , Zhong, Jun , Rogers, Laura M , Chawla, Yogesh

Science Signaling | July 7, 2026 | Volume: 19 | Issue: 945 | Pages: No page available

10.1126/scisignal.adz7366 Get It

Cytotoxic T cells produce the cytokine interferon-γ (IFN-γ). We sought to determine whether IFN-γ directly kills target cells and found that T cells used IFN-γ to kill murine melanoma cells lacking the kinases TBK1 and IKKε. In the absence of both kinases, IFN-γ induced the production of TNF receptor 1 (TNFR1) and the sensor Z-DNA binding protein 1 (ZBP1) in the tumor cells to stimulate receptor-interacting protein kinase 1 (RIPK1)–dependent apoptosis in a cell-autonomous manner. IFN-γ also enhanced the activation of nuclear factor κB (NF-κB) signaling in a TNFR1-dependent manner in cells deficient in both TBK1 and IKKε. Because IFN-γ–induced apoptosis occurred in a transcription-dependent manner with slow kinetics, STAT1 and NF-κB cooperated to activate the expression of inflammatory genes in the dying cells. Thus, IFN-γ–induced cell death was accompanied by an inflammatory signature in the absence of TBK1 and IKKε. TBK1 and IKKε not only mediated the induction of type I IFN but also inhibited RIPK1-dependent death and NF-κB–dependent inflammation. Therefore, we propose that these kinases may have gained these intertwined functions so that cells infected by pathogens that produce antagonists of TBK1 and IKKε are eliminated by IFN-γ–secreting T cells in an inflammatory manner to compensate for the inhibition of type I IFN production.